{
    "name": "obiltoxaximab",
    "comment": "Rx",
    "other_names": [
        "Anthim",
        "anthrax antitoxin"
    ],
    "classes": [
        "Antidotes",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/anthim-anthrax-antitoxin-obiltoxaximab-1000054",
    "pregnancy": {
        "common": [
            "Data are not available on use in pregnant women to inform on drug-associated risk",
            "Limited data in the form of case reports of anthrax infection in pregnant women indicate that maternal infection is associated with a high risk of maternal, fetal, and neonatal deaths, particularly in the absence of treatment"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "No evidence of harm to the pregnant New Zealand White (NZW) rabbit dam or the fetuses was observed at ~2-fold the human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Although human immunoglobulins are excreted in human milk, published data suggest that neonatal consumption of human milk does not result in substantial absorption of these maternal immunoglobulins into circulation",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Hypersensitivity and anaphylaxis have been reported during IV administration of obiltoxaximab",
                "Because of the risk of hypersensitivity and anaphylaxis, administer the IV infusion in monitored settings by trained personnel who are equipped to manage anaphylaxis",
                "Monitor patients closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration",
                "Immediately stop the infusion if hypersensitivity or anaphylaxis occur and treat appropriately"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions were the most common adverse reactions in the safety trials (see Black Box Warnings)",
                "Premedication with diphenhydramine is recommended prior to administration; diphenhydramine does not prevent anaphylaxis and may mask or delay onset of symptoms of hypersensitivity"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypersensitivity",
            "percent": "10.6"
        },
        {
            "name": "Headache",
            "percent": "8"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "5"
        },
        {
            "name": "Pruritus",
            "percent": "4"
        },
        {
            "name": "Cough",
            "percent": "3"
        },
        {
            "name": "Vessel puncture site bruise",
            "percent": "3"
        },
        {
            "name": "Infusion site swelling",
            "percent": "3"
        },
        {
            "name": "Nasal congestion",
            "percent": "2"
        },
        {
            "name": "Infusion site pain",
            "percent": "2"
        },
        {
            "name": "Urticaria",
            "percent": "2"
        },
        {
            "name": "Pain in extremity",
            "percent": "2"
        },
        {
            "name": "Anaphylaxis",
            "percent": "0.9"
        }
    ]
}